繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-830、SNP-840

SNP-830、SNP-840

Indication
Hepatotoxicity-free Analgesic
Product Advantages
1. Hepatotoxicity-free Acetaminophen prescription Combo
2. A new combination with great safety margin
Status
After the approval of SNP-810 Plan a clinical trial with / without bioequivalent study for NDA
Competitive Edge
1. No hepatotoxicity-free acetaminophen prescription Combo on the market
2. Acetaminophen prescription combos were requested by USFDA to reduce the dose to below 325 mg ( potency affected )
3. Remove or modify the FDA liver warning
4. Regain the AAP dose to 500 mg or more
5. Grab the market of other pain controllers
6. The two choose one license
Potential Market
Acetaminophen prescription Combo sales are 2.7 billion USD a year (US only)


陕西快乐十分中奖技巧 (^ω^)MG比基尼派对新手攻略 江苏快三预测一定牛 管家婆一肖两码中特 (-^O^-)MG搞笑斑马彩金 广东36选7开奖结果玩法 (^ω^)MG太阳征程奖金赔率 2o18年平特王日报 (★^O^★)MG丛林巫师_稳赢版 江西快3计划 彩票平台注册送得最多的 (*^▽^*)MG牛仔和外星人闯关 (★^O^★)MG罗马与荣耀客户端下载 怎样玩招财鞭炮可以赢 2020年彩票停售时间 (^ω^)MG女巫宝藏试玩网站 (*^▽^*)MG舞线免费试玩